Immix Biopharma, Inc. (IMMX)
NASDAQ: IMMX · Real-Time Price · USD
8.60
-0.93 (-9.76%)
At close: Apr 28, 2026, 4:00 PM EDT
8.70
+0.10 (1.22%)
After-hours: Apr 28, 2026, 7:35 PM EDT

Immix Biopharma Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2019
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2019
Selling, General & Admin
13.711.387.414.021.23
Upgrade
Research & Development
16.2611.298.744.20.13
Upgrade
Operating Expenses
29.9622.6716.148.221.35
Upgrade
Operating Income
-29.96-22.67-16.14-8.22-1.35
Upgrade
Interest Expense
----0-0.18
Upgrade
Interest & Investment Income
0.561.020.57--
Upgrade
Other Non Operating Income (Expenses)
-----22.76
Upgrade
EBT Excluding Unusual Items
-29.4-21.66-15.57-8.22-24.29
Upgrade
Other Unusual Items
-----0.09
Upgrade
Pretax Income
-29.4-21.66-15.57-8.22-24.38
Upgrade
Income Tax Expense
0.040.040.030.010.01
Upgrade
Earnings From Continuing Operations
-29.44-21.7-15.6-8.23-24.38
Upgrade
Minority Interest in Earnings
-0.080.17--
Upgrade
Net Income
-29.44-21.61-15.43-8.23-24.38
Upgrade
Net Income to Common
-29.44-21.61-15.43-8.23-24.38
Upgrade
Shares Outstanding (Basic)
332817144
Upgrade
Shares Outstanding (Diluted)
332817144
Upgrade
Shares Change (YoY)
16.55%63.11%24.87%278.13%8.82%
Upgrade
EPS (Basic)
-0.89-0.76-0.89-0.59-6.64
Upgrade
EPS (Diluted)
-0.89-0.76-0.89-0.59-6.64
Upgrade
Free Cash Flow
-24.66-15.77-11.42-7.41-1.59
Upgrade
Free Cash Flow Per Share
-0.75-0.56-0.66-0.53-0.43
Upgrade
EBITDA
-29.71-22.64-16.14-8.22-1.35
Upgrade
D&A For EBITDA
0.250.030.0100
Upgrade
EBIT
-29.96-22.67-16.14-8.22-1.35
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.